Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance 89% primary Improvement Relative Risk c19ivm.org Mourya et al. Ivermectin for COVID-19 EARLY TREATMENT Is early treatment with ivermectin beneficial for COVID-19? Retrospective 100 patients in India Improved viral clearance with ivermectin (p<0.000001) Mourya et al., Int. J. Health and Clinical Research Favors ivermectin Favors control
Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in Index Medical College Hospital and Research Center, Indore, India
Mourya et al., Int. J. Health and Clinical Research
Mourya et al., Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in.., Int. J. Health and Clinical Research
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 100 patients in India with 50 treated with ivermectin, and SOC for all patients including HCQ+AZ, showing much higher viral clearance with ivermectin. Baseline clinical status was worse in the control group. Time of testing after treatment initiation was longer in the control group (mean 7.24 days versus 5.22 days).
risk of no viral clearance, 89.4% lower, RR 0.11, p < 0.001, treatment 5 of 50 (10.0%), control 47 of 50 (94.0%), NNT 1.2, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mourya et al., 1 Apr 2021, retrospective, India, peer-reviewed, 5 authors, dosage 12mg days 1-7.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: International Journal of Health and Clinical Research, 2021;4(6):265-267 e-ISSN: 2590-3241, p-ISSN: 2590-325X ____________________________________________________________________________________________________________________________________________ Original Research Article Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in Index Medical College Hospital and Research Center, Indore, India Sudhir Mourya1, Ajay Singh Thakur2, Deepti Singh Hada3*, Vibhu Sagar Kulshreshtha4, Yash Sharma5 1 Professor and Head, Department of Internal Medicine, Index Medical College Hospital and Research Center, Indore, Madhya Pradesh, India 2 Associate Professor, Department of Orthopedics, Index Medical College Hospital and Research Center, Indore, Madhya Pradesh, India 3 Assistant Dean and Assistant Professor, Department of Oral Medicine and Radiology, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India 4 PG Resident, Department of Internal Medicine, Index Medical College Hospital and Research Center, Indore, Madhya Pradesh, India 5 PG Resident, Department of Orthopedics, Index Medical College Hospital and Research Center, Indore, Madhya Pradesh, India Received: 12-01-2021 / Revised: 13-03-2021 / Accepted:27-03-2021 Abstract Background: SARS-CoV-2 is a novel virus that first emerged in Wuhan, China. Considering the novel nature of the coronavirus, there are not yet any proven treatment strategies. In this emergency, there is no specific pharmacologic treatment that specifically targets and kill the virus or control the infection and improve the clinical outcomes. Several drugs were repurposed for this illness based on in-vitro studies or minimal evidence to combat the rapid spread of the COVID-19 pandemic.Aims and objectives: To compare efficacy of two regimens’, Regimen 1 (hydroxychloroquine and azithromycin) and Regimen 2 (hydroxychloroquine, azithromycin and ivermectin) in Covid-19 positive patients. Materials and methods: An observation study on 100 Covid 19 positive patients having age between 20-60 years of either sex was conducted from April to May 2020. Patients below 20 years of and above 60 years of age and having chronic conditions like hypertension, diabetes and others were excluded. Group 1 received oral hydroxychloroquine 400 mg twice a day with azithromycin 500 mg once a day. Both medications were given by per oral route for a period of 7 days. Group 2 received hydroxychloroquine 400 mg twice a day with azithromycin 500 mg once a day and ivermectin 12 mg once a day. All medications were given by per oral route for a period of 7 days.Results: Mean age of patients in Group 1 and Group 2 was 37.62 ± 11.609 years and 38.20±11.73 years respectively (p=0.804). No significant difference was obtained between the SpO2 concentration (p=0.778). When we did final the COVID-19 testing, it showed that majority of the patients were found negative in the group 2, whereas 94% were found to be positive in the group 1. This difference was statistically significant with the p value of <0.001. Conclusion: The treatment with HCQ, azithromycin, and ivermectin had a better success rate compared to HCQ and azithromycin. Based on the results, ivermectin could be the potential therapeutic agents for the COVID-19 disease. The study had various limitations; so further randomized controlled trial is required for the results to be implemented on the larger population. Keywords: HCQ, azithromycin,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit